Migdal Insurance & Financial Holdings Ltd. Nektar Therapeutics Transaction History

Migdal Insurance & Financial Holdings Ltd.

$6.97 Billion
Q4 2024

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 13, 2019	SELL	$30.43 - $56.65 $37,428 - $69,679	-1,230 Closed	0 $0
Q3 2018 Nov 08, 2018	BUY	$46.46 - $68.49 $35,356 - $52,120	761 Added 162.26%	1,230 $75,000
Q2 2018 Aug 01, 2018	BUY	$46.25 - $104.45 $20,997 - $47,420	454 Added 3026.67%	469 $23,000
Q1 2018 May 02, 2018	BUY	$57.4 - $108.44 $861 - $1,626	15 New	15 $2,000

Others Institutions Holding NKTR

# of Institutions

146

Shares Held

140M

Call Options Held

32.6K

Put Options Held

14.1K

Deep Track Capital, LP Greenwich, CT

15.9M
Shares

$13.4 Million
0.76% of portfolio
Black Rock Inc. New York, NY

15.2M
Shares

$12.7 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

13.1M
Shares

$11 Million
0.0% of portfolio
Eventide Asset Management, LLC Boston, MA

9.4M
Shares

$7.9 Million
0.22% of portfolio
Samlyn Capital, LLC New York, NY

9.2M
Shares

$7.73 Million
0.19% of portfolio

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $157M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Migdal Insurance & Financial Holdings Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Migdal Insurance & Financial Holdings Ltd. with notifications on news.

Account